Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1113369
Abstract: Background Tislelizumab is an anti-programmed cell death 1 (PD-1) monoclonal antibody engineered to minimize binding to Fcγ receptors. It has been used to treat several solid tumors. However, its efficacy and toxicity, and the predictive… read more here.
Keywords: cervical cancer; pfs; tislelizumab; patients treated ... See more keywords